Non-small cell lung cancer

• A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-ag … Recruiting
  2024-520164-33-00 5 2025-12-09 "Non-Small Cell Lung Cancer"
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 "Non-Small Cell Lung Cancer (NSCLC)"
• A randomized multicenter Phase II trial evaluating oral pooled fecal microbiotherapy (MaaT033) concomitant to Cemiplimab (CB) versus best in … Recruiting
  2024-517018-14-00 4 2025-11-17 "Advanced non-small cell lung cancer"
• A Study in TKI-naive Patients With Advanced ALK-Positive NSCLC ( ALKAZAR ) Recruiting
  2024-517553-26-00 5 2025-11-12 "Advanced ALK-positive non-small cell lung cancer (NSCLC)"
• TransBronchial Needle injection of Tremelimumab in early-stage NSCLC patients (TALENT) Recruiting
  2024-511878-67-00 9 2025-11-03 "Non small cell lung cancer"
• A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors Recruiting
  2025-521535-36-00 1 2025-11-03 "Locally advanced, metastatic NSCLC, CRC, or HNSCC that has r"
• A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unre … Recruiting
  2024-512421-92-00 7 2025-10-14 "Unresectable, Locally Advanced or Metastatic Cancer"
• Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of NSCLC Recruiting
  2024-519883-42-00 5 2025-10-08
• Study of zoldonrasib with or without daraxonrasib and other anticancer drugs in patients with RAS G12D-mutant non-small cell lung cancer (NS … Recruiting
  2025-521147-21-00 4 2025-10-08 "Lung Cancer"
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as Firs … Recruiting
  2024-518586-10-00 10 2025-09-18 "Non-Squamous Non-Small Cell Lung Cancer"
• Single Arm Study of WSD0922-FU for NSCLC Patients with C797S mutation Recruiting
  2024-519713-65-00 4 2025-09-04 "Non-Small Cell Lung Cancer"
• A Phase 2 study of JNJ-90301900 with chemoradiation and durvalumab for non-small cell lung cancer Recruiting
  2024-518276-32-00 4 2025-08-29 "Locally advanced and unresectable Stage III non-small cell l"
• Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting
  2024-518154-16-00 5 2025-08-27 "non-small cell lung cancer"
• A First-in-human Study to Evaluate the Safety and Anticancer Effect of Several Doses of TH9619 in Patients with Advanced Cancer (ODIN). Recruiting
  2024-519639-40-00 1 2025-08-18 "Solid tumors (including Non-Small Cell Lung Cancer (NSCLC), "
• Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in pati … Recruiting
  2023-510356-23-00 1 2025-07-18 "Locally advanced or metastatic unresectable colorectal cance"
• Randomized phase II trial of Cemiplimab plus OSE2101 (TEDOPI®) as maintenance  therapy in ctDNA positive NSCLC. Recruiting
  2024-519262-42-00 4 2025-07-15 "NSCLC non-small cell lung cancer"
• Study of the treatment of patients with non-small cell lung cancer with metastasis with Cemiplimab and subsequent treatment with Cemiplimab … Recruiting
  2024-518812-38-00 4 2025-07-02 "Non-small cell lung cancer (NSCLC)"
• A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lun … Recruiting
  2023-506539-14-00 3 2025-05-27 "Oncology"
• A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting
  2023-506327-29-00 5 2025-05-14 "Non-Small Cell Lung Cancer"
• A study to evaluate the benefit of adding durvalumab after chemotherapy, durvalumab and surgery in patients with early-stage, operable, non- … Recruiting
  2023-508773-82-00 5 2025-05-06 "Stage IIB-IIIB (N2) resectable non small cell lung cancer"
• Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting
  2024-514465-18-00 9 2025-04-23 "Advanced or Metastatic Non-Squamous NSCLC"
• First -in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors Recruiting
  2023-507937-14-00 7 2025-03-25 "Metastatic Solid Tumor"
• A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 I … Recruiting
  2024-515307-19-00 1 2025-03-24 "Advanced, or metastatic solid tumors with methylthioadenosin"
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Recruiting
  2024-513285-19-00 1 2025-03-14 "Pancreatic Ductal Adeno Carcinoma"

Showing 49–72 of 239 trials